Evidence Level
Moderate
Red clover isoflavones have been extensively studied for menopausal symptoms with mixed but generally positive results. The Cochrane review by Lethaby et al. (2007) found a small but significant reduction in hot flash frequency. Tice et al. (2003) conducted a rigorous RCT of 252 menopausal women comparing Promensil (82mg isoflavones), Rimostil (57mg isoflavones), and placebo, finding modest but inconsistent benefits over 12 weeks. The preferential ERβ binding of red clover isoflavones is a distinguishing feature, as ERβ activation in bone and vascular tissue may provide benefits without the proliferative risks associated with ERα activation in breast and uterine tissue.